TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker

E. L. Mayer, V. Abramson, R. Jankowitz, C. Falkson, P. K. Marcom, T. Traina, L. Carey, M. Rimawi, J. Specht, K. Miller, V. Stearns, N. Tung, C. Perou, A. L. Richardson, K. Componeschi, L. Trippa, Z. Tan-Wasielewski, K. Timms, I. Krop, A. C. WolffE. P. Winer

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker'. Together they form a unique fingerprint.

Medicine & Life Sciences